A prospective study of pregravid oral contraceptive use in relation to fetal growth.
OBJECTIVE
Because oral contraceptives are so widely used, any health consequences may have substantial public health implications. Whether pregravid oral contraceptives could affect subsequent pregnancies has not been adequately studied. The study objectives were to examine whether pregravid oral contraceptive use affects fetal growth and pregnancy hormone levels.


METHODS
A prospective study of pregnant women followed through pregnancy.


METHODS
A major teaching hospital in Boston, USA.


METHODS
Two hundred and sixty Caucasian pregnant women, with a mean age of 31, and a parity of no more than two. Seventy-nine percent of the women were pregravid oral contraceptive users.


METHODS
Exposure and covariate data were collected through structured questionnaires. Blood was drawn for hormonal analysis during the 16th and 27th gestational week. Information on pregravid oral contraceptive use included duration and recency of use, and oral contraceptive formulation. Multivariate regression models were used to examine the effect of pregravid oral contraceptive use on birth outcomes and the studied pregnancy hormones.


METHODS
Birthweight, placental weight, gestational age, pregnancy hormone levels of oestriol and progesterone at 16th and 27th gestational week.


RESULTS
Adjusting for confounders, pregravid oral contraceptive use increased birthweight (mean difference =+207.3 g, 95% CI =+77.6 to +337.1) and placental weight (mean difference =+64.9 g, 95% CI =+13.0 to +116.9) compared with never use. Women with prior oral contraceptive use had higher levels of serum progesterone (P= 0.002) and oestriol (P= 0.12) at the 27th gestational week measurement. The effect on birthweight, placental weight and hormones was stronger among those using oral contraceptives in the previous year and those using a high progestin/high oestrogen potency preparation.


CONCLUSIONS
Pregravid oral contraceptive use is positively associated with fetal growth, and this effect may be mediated through oestriol and progesterone.
Mucci
Lorelei A
LA
Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA.
Lagiou
Pagona
P
Hsieh
Chung-Cheng
CC
Tamimi
Rulla
R
Hellerstein
Susan
S
Vatten
Lars
L
Adami
Hans-Olov
HO
Cnattingius
Sven
S
Trichopoulos
Dimitrios
D
D000293:Adolescent; D000328:Adult; D003276:Contraceptives, Oral / Q000009:adverse effects*; D005314:Embryonic and Fetal Development / Q000187:drug effects*; D005260:Female; D020073:Gravidity; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D008297:Male; D008423:Maternal Age; D018811:Maternal Exposure; D016742:Preconception Care; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies
D003276:Contraceptives, Oral